IL-18 known as IFN-γ inducing factor enhances antitumor immunity in various cancer types as previously reported.54 However, clinical administration of recombinant IL-18 alone has been curtailed due to its lack of strong efficacy in clinical trials,55 the level of IL-37 should be considered in this therapeutic strategy. This evidence concerns the gene IFNG and cancer.